Company:  CTI BIOPHARMA CORP (CTIC)
Form Type:  8-K
Filing Date:  4/27/2012 
CIK:  0000891293 
Address:  3101 WESTERN AVENUE
SUITE 800
 
City, State, Zip:  SEATTLE, Washington 98121 
Telephone:  (206) 282-7100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.76  
Change: 
-0.03 (-0.63%)  
Trade Time: 
May 24  
Market Cap: 
$275.97M
Trade CTIC now with

© 2018  
Description of Business
We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. Our goal is to build a profitable company by generating income from products we develop and commercialize, either alone or with partners. We are currently concentrating our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are primarily focused on evaluating pacritinib for the treatment of adult patients with myelofibrosis and the further development of PIXUVRI worldwide, for which our partner, Les Laboratoires Servier and Institut de Recherches Internationales Servier, or collectively Servier, has commercialization rights outside the United States, or the U.S. PIXUVRI PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 99.1